Buy Procardia Online

Nifedipine (nifedipine)

OTHER BRAND NAMES

Procardia

THERAPEUTIC CLASS

Calcium channel blocker (CCB) (dihydropyridine)

DEA CLASS

RX

INDICATIONS

Management of vasospastic angina and chronic stable angina (effort-associated angina) w/o evidence of vasospasm in patients who remain symptomatic despite adequate doses of β-blockers and/or organic nitrates, or who cannot tolerate those agents.

ADULT DOSAGE

Angina

Vasospastic Angina/Chronic Stable Angina (Effort-Associated Angina):
Initial:
10mg tid
Usual Range: 10-20mg tid, or 20-30mg tid-qid in patients w/ evidence of coronary artery spasm
Titrate: Adjust dose over a 7- to 14-day period; may increase dose from 10mg tid to 20mg tid, then 30mg tid over a 3-day period based on physical activity level, attack frequency, and SL nitroglycerin consumption. May increase in 10mg increments over 4- to 6-hr periods in hospitalized patients to control pain and arrhythmias due to ischemia; single dose should rarely exceed 30mg
Max: 180mg/day

DOSING CONSIDERATIONS

Discontinuation
Decrease dose gradually w/ close supervision

Other Important Considerations
Avoid coadministration w/ grapefruit juice

ADMINISTRATION

Oral route

Swallow cap whole.

HOW SUPPLIED

Cap: 20mg; (Procardia) 10mg

WARNINGS/PRECAUTIONS

May cause hypotension; monitor BP initially and w/ titration. Should not be used for acute reduction of BP or control of essential HTN. May increase frequency, duration and/or severity of angina or acute myocardial infarction (AMI), particularly w/ severe obstructive coronary artery disease (CAD). Avoid w/ acute coronary syndrome (when infarction may be imminent) and w/in the 1st week or 2 after MI. May develop heart failure (HF) after beginning therapy; increased risk w/ tight aortic stenosis. Mild to moderate peripheral edema associated w/ arterial vasodilation may occur; differentiate peripheral edema from the effects of increasing left ventricular dysfunction in patients w/ angina complicated by congestive heart failure (CHF). Transient elevations of enzymes (eg, alkaline phosphatase, CPK, LDH, SGOT, SGPT), cholestasis w/ or w/o jaundice, and allergic hepatitis reported (rare). May decrease platelet aggregation and increase bleeding time. Positive direct Coombs test w/ or w/o hemolytic anemia reported. Reversible elevations in BUN and SrCr reported rarely in patients w/ chronic renal insufficiency.

ADVERSE REACTIONS

Dizziness, lightheadedness, giddiness, flushing, heat sensation, headache, weakness, nausea, heartburn, muscle cramps, tremor, peripheral edema, nervousness, mood changes, palpitation.

DRUG INTERACTIONS

β-blockers may increase the likelihood of CHF, severe hypotension, or angina exacerbation; avoid abrupt β-blocker withdrawal. Severe hypotension and/or increased fluid volume requirements reported together w/ β-blockers and fentanyl or other narcotic analgesics; if condition permits, allow sufficient time (at least 36 hrs) for nifedipine to be washed out prior to surgery w/ fentanyl. May increase digoxin levels; monitor when initiating, adjusting, and discontinuing therapy to avoid possible over- or under-digitalization. May decrease plasma levels of quinidine. May increase PT w/ coumarin anticoagulants. Cimetidine may increase levels; caution during titration. Phenytoin may lower systemic exposure to nifedipine; avoid w/ phenytoin or any known CYP3A4 inducer. CYP3A inhibitors (eg, fluconazole, itraconazole, clarithromycin) may increase exposure; monitor carefully and consider initiating nifedipine at lowest dose available. Increased plasma concentrations w/ grapefruit juice. Monitor w/ other medications known to lower BP.

PREGNANCY AND LACTATION

Category C, caution in nursing.

MECHANISM OF ACTION

Calcium channel blocker (dihydropyridine); inhibits Ca2+ ion influx into cardiac muscle and smooth muscle. Angina: has not been established; believed to act by relaxation and prevention of coronary artery spasm and reduction of oxygen utilization.

PHARMACOKINETICS

Absorption: Rapid and fully absorbed; Tmax=30 min. Distribution: Plasma protein binding (92-98%); found in breast milk. Metabolism: Liver, extensive. Elimination: Kidneys (80%); T1/2=2 hrs.

ASSESSMENT

Assess for acute coronary syndrome, severe obstructive CAD, aortic stenosis, hepatic/renal impairment, recent β-blocker withdrawal, hypersensitivity to the drug, pregnancy/nursing status, and possible drug interactions.

MONITORING

Monitor for excessive hypotension, increased frequency, duration and/or severity of angina and/or AMI, peripheral edema, HF, cholestasis w/ or w/o jaundice, allergic hepatitis, and other adverse reactions. Monitor BP, CPK, LFTs, BUN, SrCr, for decreased platelet aggregation, and increased bleeding time.

PATIENT COUNSELING

Inform about potential risks/benefits of drug. Instruct to notify physician if pregnant/nursing or if any adverse reactions occur.

STORAGE

15-25°C (59-77°F). Protect from light and moisture.

TAGS

buy nifedipine online, purchase nifedipine, purchase procardia, procardia generic nifedipine, purchase procardia online, buy procardia online, order nifedipine, generic procardia, buy nifedipine, adalat cc vs procardia xl, adalat vs procardia, order procardia online, buy cheap nifedipine, purchase nifedipine online, generic nifedipine, order procardia, buy procardia, buy cheap procardia, order nifedipine online